The United Kingdom has approved Myqorzo, a new oral medication for treating obstructive hypertrophic cardiomyopathy (oHCM), a rare heart condition that can restrict blood flow and affect the heart’s ability to pump effectively.
The approval by the UK’s medicines regulator, along with a recommendation from the National Institute for Health and Care Excellence (NICE), clears the way for eligible patients in England and Wales to receive the treatment through the National Health Service (NHS).
New Treatment for Obstructive Hypertrophic Cardiomyopathy
Myqorzo is designed to treat obstructive hypertrophic cardiomyopathy (oHCM), a condition in which the heart muscle becomes abnormally thick, making it harder for blood to leave the heart.
According to health authorities, around one in every 500 people in the UK has hypertrophic cardiomyopathy (HCM), with nearly half of all cases believed to be inherited.
NICE Recommends NHS Coverage
NICE has recommended Myqorzo for adults with symptomatic oHCM classified as New York Heart Association (NYHA) Class II or III.
The medicine can be prescribed alongside standard treatments or used on its own when other therapies are unsuitable. NICE estimates that approximately 6,600 patients in England and Wales could benefit from the treatment.
How Myqorzo Works
Myqorzo belongs to a class of medicines known as cardiac myosin inhibitors. It works by targeting the heart muscle to reduce obstruction in blood flow and improve the heart’s pumping function.
The drug is in the same therapeutic class as Camzyos, another treatment used for obstructive hypertrophic cardiomyopathy.
Also Read :JPMC Karachi to Offer Free Advanced Breast Cancer Radiation Treatment
Today's E-Paper